Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Variably protease-sensitive prionopathy presenting within ALS/FTD spectrum.

Vicente-Pascual M, Rossi M, Gámez J, Lladó A, Valls J, Grau-Rivera O, Ávila Polo R, Llorens F, Zerr I, Ferrer I, Nos C, Parchi P, Sánchez-Valle R, Gelpí E.

Ann Clin Transl Neurol. 2018 Sep 21;5(10):1297-1302. doi: 10.1002/acn3.632. eCollection 2018 Oct.

2.

Distinct microglia profile in Creutzfeldt-Jakob disease and Alzheimer's disease is independent of disease kinetics.

Krbot K, Hermann P, Skorić MK, Zerr I, Sepulveda-Falla D, Goebel S, Matschke J, Krasemann S, Glatzel M.

Neuropathology. 2018 Oct 15. doi: 10.1111/neup.12517. [Epub ahead of print]

PMID:
30318820
3.

Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease.

Kanata E, Golanska E, Villar-Piqué A, Karsanidou A, Dafou D, Xanthopoulos K, Schmitz M, Ferrer I, Karch A, Sikorska B, Liberski PP, Sklaviadis T, Zerr I, Llorens F.

J Clin Neurosci. 2018 Oct 9. pii: S0967-5868(18)31450-4. doi: 10.1016/j.jocn.2018.09.031. [Epub ahead of print]

PMID:
30309804
4.

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease.

Kruse N, Heslegrave A, Gupta V, Foiani M, Villar-Piqué A, Schmitz M, Lehmann S, Teunissen C, Blennow K, Zetterberg H, Mollenhauer B, Zerr I, Llorens F.

Alzheimers Dement (Amst). 2018 Jul 7;10:461-470. doi: 10.1016/j.dadm.2018.06.005. eCollection 2018.

5.

Diagnostic challenges in rapidly progressive dementia.

Zerr I, Hermann P.

Expert Rev Neurother. 2018 Oct;18(10):761-772. doi: 10.1080/14737175.2018.1519397. Epub 2018 Sep 17.

PMID:
30173564
6.

Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein.

Albus A, Gold M, Bach JP, Burg-Roderfeld M, Jördens M, Kirchhein Y, Kronimus Y, Mengel D, Zerr I, Dodel R.

PLoS One. 2018 Aug 29;13(8):e0202954. doi: 10.1371/journal.pone.0202954. eCollection 2018.

7.

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.

Schmitz M, Villar-Piqué A, Llorens F, Gmitterová K, Hermann P, Varges D, Zafar S, Lingor P, Vanderstichele H, Demeyer L, Stoops E, Trojanowski JQ, Lee VM, Zerr I.

Mol Neurobiol. 2018 Aug 22. doi: 10.1007/s12035-018-1313-4. [Epub ahead of print]

PMID:
30136097
8.

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study.

Kranaster L, Hoyer C, Aksay SS, Bumb JM, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Janke C, Thiel M, Sartorius A.

Neuropsychobiology. 2019;77(1):13-22. doi: 10.1159/000491401. Epub 2018 Aug 17.

PMID:
30121652
9.

Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.

Gmitterová K, Gawinecka J, Llorens F, Varges D, Valkovič P, Zerr I.

Eur Arch Psychiatry Clin Neurosci. 2018 Aug 6. doi: 10.1007/s00406-018-0928-9. [Epub ahead of print]

PMID:
30083957
10.

MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives.

Kanata E, Thüne K, Xanthopoulos K, Ferrer I, Dafou D, Zerr I, Sklaviadis T, Llorens F.

Front Aging Neurosci. 2018 Jul 23;10:220. doi: 10.3389/fnagi.2018.00220. eCollection 2018.

11.

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases.

Villar-Piqué A, Schmitz M, Lachmann I, Karch A, Calero O, Stehmann C, Sarros S, Ladogana A, Poleggi A, Santana I, Ferrer I, Mitrova E, Žáková D, Pocchiari M, Baldeiras I, Calero M, Collins SJ, Geschwind MD, Sánchez-Valle R, Zerr I, Llorens F.

Mol Neurobiol. 2018 Jul 30. doi: 10.1007/s12035-018-1251-1. [Epub ahead of print]

PMID:
30062673
12.

Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges.

Abu-Rumeileh S, Redaelli V, Baiardi S, Mackenzie G, Windl O, Ritchie DL, Didato G, Hernandez-Vara J, Rossi M, Capellari S, Imperiale D, Rizzone MG, Belotti A, Sorbi S, Rozemuller AJM, Cortelli P, Gelpi E, Will RG, Zerr I, Giaccone G, Parchi P.

Ann Neurol. 2018 Sep;84(3):347-360. doi: 10.1002/ana.25300. Epub 2018 Aug 31.

PMID:
30048013
13.

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD.

Ermann N, Lewczuk P, Schmitz M, Lange P, Knipper T, Goebel S, Kornhuber J, Zerr I, Llorens F.

Ann Clin Transl Neurol. 2018 May 26;5(7):883-887. doi: 10.1002/acn3.584. eCollection 2018 Jul.

14.

Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance.

Hermann P, Laux M, Glatzel M, Matschke J, Knipper T, Goebel S, Treig J, Schulz-Schaeffer W, Cramm M, Schmitz M, Zerr I.

Neurology. 2018 Jul 24;91(4):e331-e338. doi: 10.1212/WNL.0000000000005860. Epub 2018 Jun 22.

PMID:
29934424
15.

Sporadic Creutzfeldt-Jakob disease.

Zerr I, Parchi P.

Handb Clin Neurol. 2018;153:155-174. doi: 10.1016/B978-0-444-63945-5.00009-X.

PMID:
29887134
16.

Amplification and Detection of Minuscule Amounts of Misfolded Prion Protein by Using the Real-Time Quaking-Induced Conversion.

Schmitz M, Candelise N, Llorens F, Zerr I.

Methods Mol Biol. 2018;1779:257-263. doi: 10.1007/978-1-4939-7816-8_16.

PMID:
29886538
17.

Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie.

Llorens F, Barrio T, Correia Â, Villar-Piqué A, Thüne K, Lange P, Badiola JJ, Schmitz M, Lachmann I, Bolea R, Zerr I.

Mol Neurobiol. 2018 Nov;55(11):8586-8591. doi: 10.1007/s12035-018-1014-z. Epub 2018 Mar 23.

PMID:
29572672
18.

Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Villar-Piqué A, Schmitz M, Candelise N, Ventura S, Llorens F, Zerr I.

Mol Neurobiol. 2018 Sep;55(9):7588-7605. doi: 10.1007/s12035-018-0926-y. Epub 2018 Feb 10. Review.

PMID:
29429052
19.

Animal TSEs and public health: What remains of past lessons?

Zafar S, Shafiq M, Andréoletti O, Zerr I.

PLoS Pathog. 2018 Feb 8;14(2):e1006759. doi: 10.1371/journal.ppat.1006759. eCollection 2018 Feb. No abstract available.

20.

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.

Zerr I, Schmitz M, Karch A, Villar-Piqué A, Kanata E, Golanska E, Díaz-Lucena D, Karsanidou A, Hermann P, Knipper T, Goebel S, Varges D, Sklaviadis T, Sikorska B, Liberski PP, Santana I, Ferrer I, Zetterberg H, Blennow K, Calero O, Calero M, Ladogana A, Sánchez-Valle R, Baldeiras I, Llorens F.

Alzheimers Dement. 2018 Jun;14(6):751-763. doi: 10.1016/j.jalz.2017.12.008. Epub 2018 Feb 3.

PMID:
29391125
21.

Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease.

Maass F, Michalke B, Leha A, Boerger M, Zerr I, Koch JC, Tönges L, Bähr M, Lingor P.

J Neurochem. 2018 May;145(4):342-351. doi: 10.1111/jnc.14316. Epub 2018 Apr 2.

PMID:
29388213
22.

Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis.

Llorens F, Thüne K, Martí E, Kanata E, Dafou D, Díaz-Lucena D, Vivancos A, Shomroni O, Zafar S, Schmitz M, Michel U, Fernández-Borges N, Andréoletti O, Del Río JA, Díez J, Fischer A, Bonn S, Sklaviadis T, Torres JM, Ferrer I, Zerr I.

PLoS Pathog. 2018 Jan 22;14(1):e1006802. doi: 10.1371/journal.ppat.1006802. eCollection 2018 Jan.

23.

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias.

Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, Ozbay D, Correia S, Correia Â, Milosevic I, Andréoletti O, Fernández-Borges N, Vorberg IM, Glatzel M, Sklaviadis T, Torres JM, Krasemann S, Sánchez-Valle R, Ferrer I, Zerr I.

Mol Neurodegener. 2017 Nov 10;12(1):83. doi: 10.1186/s13024-017-0226-4.

24.

Cerebrospinal fluid in Creutzfeldt-Jakob disease.

Zerr I, Zafar S, Schmitz M, Llorens F.

Handb Clin Neurol. 2017;146:115-124. doi: 10.1016/B978-0-12-804279-3.00008-3. Review.

PMID:
29110766
25.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27. Review.

PMID:
29076399
26.

DNA versus RNA oxidation in Parkinson's disease: Which is more important?

Gmitterová K, Gawinecka J, Heinemann U, Valkovič P, Zerr I.

Neurosci Lett. 2018 Jan 1;662:22-28. doi: 10.1016/j.neulet.2017.09.048. Epub 2017 Sep 27.

PMID:
28963060
27.

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia.

Llorens F, Schmitz M, Knipper T, Schmidt C, Lange P, Fischer A, Hermann P, Zerr I.

Front Aging Neurosci. 2017 Sep 12;9:289. doi: 10.3389/fnagi.2017.00289. eCollection 2017.

28.

α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B.

Ferreira DG, Temido-Ferreira M, Vicente Miranda H, Batalha VL, Coelho JE, Szegö ÉM, Marques-Morgado I, Vaz SH, Rhee JS, Schmitz M, Zerr I, Lopes LV, Outeiro TF.

Nat Neurosci. 2017 Nov;20(11):1569-1579. doi: 10.1038/nn.4648. Epub 2017 Sep 25.

PMID:
28945221
29.

Molecular basis of Cd+2 stress response in Candida tropicalis.

Khan Z, Rehman A, Nisar MA, Zafar S, Hussain SZ, Zerr I, Hussain I, Waseem M, Arif M.

Appl Microbiol Biotechnol. 2017 Oct;101(20):7715-7728. doi: 10.1007/s00253-017-8503-2. Epub 2017 Sep 17.

PMID:
28920150
30.

MicroRNA Expression in the Locus Coeruleus, Entorhinal Cortex, and Hippocampus at Early and Middle Stages of Braak Neurofibrillary Tangle Pathology.

Llorens F, Thüne K, Andrés-Benito P, Tahir W, Ansoleaga B, Hernández-Ortega K, Martí E, Zerr I, Ferrer I.

J Mol Neurosci. 2017 Oct;63(2):206-215. doi: 10.1007/s12031-017-0971-4. Epub 2017 Sep 5.

PMID:
28871468
31.

Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies.

Candelise N, Schmitz M, Da Silva Correia SM, Arora AS, Villar-Piqué A, Zafar S, Llorens F, Cramm M, Zerr I.

Expert Rev Mol Diagn. 2017 Oct;17(10):897-904. doi: 10.1080/14737159.2017.1368389. Epub 2017 Sep 8. Review.

PMID:
28817974
32.

Prion Protein Interactome: Identifying Novel Targets in Slowly and Rapidly Progressive Forms of Alzheimer's Disease.

Zafar S, Shafiq M, Younas N, Schmitz M, Ferrer I, Zerr I.

J Alzheimers Dis. 2017;59(1):265-275. doi: 10.3233/JAD-170237.

PMID:
28671123
33.

Neuropsychological Symptoms in Sporadic Creutzfeldt-Jakob Disease Patients in Germany.

Krasnianski A, Bohling GT, Heinemann U, Varges D, Meissner B, Schulz-Schaeffer WJ, Reif A, Zerr I.

J Alzheimers Dis. 2017;59(1):329-337. doi: 10.3233/JAD-161129.

PMID:
28598840
34.

Cytoskeleton-Associated Risk Modifiers Involved in Early and Rapid Progression of Sporadic Creutzfeldt-Jakob Disease.

Zafar S, Younas N, Sheikh N, Tahir W, Shafiq M, Schmitz M, Ferrer I, Andréoletti O, Zerr I.

Mol Neurobiol. 2018 May;55(5):4009-4029. doi: 10.1007/s12035-017-0589-0. Epub 2017 Jun 1.

PMID:
28573459
35.

Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease.

Llorens F, Thüne K, Sikorska B, Schmitz M, Tahir W, Fernández-Borges N, Cramm M, Gotzmann N, Carmona M, Streichenberger N, Michel U, Zafar S, Schuetz AL, Rajput A, Andréoletti O, Bonn S, Fischer A, Liberski PP, Torres JM, Ferrer I, Zerr I.

Acta Neuropathol Commun. 2017 Apr 27;5(1):35. doi: 10.1186/s40478-017-0431-y.

36.

Effect of Metformin on Adult Hippocampal Neurogenesis: Comparison with Donepezil and Links to Cognition.

Ahmed S, Mahmood Z, Javed A, Hashmi SN, Zerr I, Zafar S, Zahid S.

J Mol Neurosci. 2017 May;62(1):88-98. doi: 10.1007/s12031-017-0915-z. Epub 2017 Apr 4.

PMID:
28378260
37.

Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms.

Garcia-Esparcia P, López-González I, Grau-Rivera O, García-Garrido MF, Konetti A, Llorens F, Zafar S, Carmona M, Del Rio JA, Zerr I, Gelpi E, Ferrer I.

Front Neurol. 2017 Mar 13;8:89. doi: 10.3389/fneur.2017.00089. eCollection 2017.

38.

Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations.

Llorens F, Zarranz JJ, Fischer A, Zerr I, Ferrer I.

Curr Neurol Neurosci Rep. 2017 Apr;17(4):30. doi: 10.1007/s11910-017-0743-0. Review.

PMID:
28324299
39.

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.

Llorens F, Kruse N, Karch A, Schmitz M, Zafar S, Gotzmann N, Sun T, Köchy S, Knipper T, Cramm M, Golanska E, Sikorska B, Liberski PP, Sánchez-Valle R, Fischer A, Mollenhauer B, Zerr I.

Mol Neurobiol. 2018 Mar;55(3):2249-2257. doi: 10.1007/s12035-017-0479-5. Epub 2017 Mar 21.

40.

Biosorption behavior and proteomic analysis of Escherichia coli P4 under cadmium stress.

Khan Z, Rehman A, Nisar MA, Zafar S, Zerr I.

Chemosphere. 2017 May;174:136-147. doi: 10.1016/j.chemosphere.2017.01.132. Epub 2017 Jan 27.

PMID:
28161514
41.

Cellular prion protein mediates early apoptotic proteome alternation and phospho-modification in human neuroblastoma cells.

Zafar S, Behrens C, Dihazi H, Schmitz M, Zerr I, Schulz-Schaeffer WJ, Ramljak S, Asif AR.

Cell Death Dis. 2017 Jan 19;8(1):e2557. doi: 10.1038/cddis.2016.384.

42.

Progress in CSF biomarker discovery in sCJD.

Llorens F, Schmitz M, Zerr I.

Oncotarget. 2017 Jan 24;8(4):5666-5667. doi: 10.18632/oncotarget.13998. No abstract available.

43.

Cellular Prion Protein (PrPc) and Hypoxia: True to Each Other in Good Times and in Bad, in Sickness, and in Health.

Ramljak S, Herlyn H, Zerr I.

Front Cell Neurosci. 2016 Dec 19;10:292. doi: 10.3389/fncel.2016.00292. eCollection 2016.

44.

Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs.

Llorens F, Karch A, Golanska E, Schmitz M, Lange P, Sikorska B, Liberski PP, Zerr I.

Dement Geriatr Cogn Disord. 2017;43(1-2):71-80. doi: 10.1159/000454802. Epub 2017 Jan 6.

PMID:
28056460
45.

Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt-Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress.

Tahir W, Zafar S, Llorens F, Arora AS, Thüne K, Schmitz M, Gotzmann N, Kruse N, Mollenhauer B, Torres JM, Andréoletti O, Ferrer I, Zerr I.

Mol Neurobiol. 2018 Jan;55(1):517-537. doi: 10.1007/s12035-016-0294-4. Epub 2016 Dec 14.

PMID:
27975168
46.

Electroconvulsive therapy selectively enhances amyloid β 1-42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study.

Kranaster L, Aksay SS, Bumb JM, Janke C, Alonso A, Hoyer C, Zerr I, Schmitz M, Hausner L, Frölich L, Sartorius A.

Eur Neuropsychopharmacol. 2016 Dec;26(12):1877-1884. doi: 10.1016/j.euroneuro.2016.11.004. Epub 2016 Nov 18.

PMID:
27876183
47.

Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.

Llorens F, Kruse N, Schmitz M, Gotzmann N, Golanska E, Thüne K, Zejneli O, Kanata E, Knipper T, Cramm M, Lange P, Zafar S, Sikorska B, Liberski PP, Mitrova E, Varges D, Schmidt C, Sklaviadis T, Mollenhauer B, Zerr I.

Alzheimers Dement. 2017 Jun;13(6):710-719. doi: 10.1016/j.jalz.2016.09.013. Epub 2016 Nov 18.

PMID:
27870938
48.

Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients.

Schmitz M, Llorens F, Pracht A, Thom T, Correia Â, Zafar S, Ferrer I, Zerr I.

Aging (Albany NY). 2016 Nov 14;8(11):2927-2935. doi: 10.18632/aging.101101.

49.

Doxycycline in early CJD: a double-blinded randomised phase II and observational study.

Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Schulz-Schaeffer WJ, Krasnianski A, Breithaupt M, Fincke F, Kramer K, Friede T, Zerr I.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):119-125. doi: 10.1136/jnnp-2016-313541. Epub 2016 Nov 2.

50.

Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia.

Karch A, Llorens F, Schmitz M, Arora AS, Zafar S, Lange P, Schmidt C, Zerr I.

J Alzheimers Dis. 2016 Oct 18;54(4):1385-1393.

PMID:
27589519

Supplemental Content

Support Center